RATIONALE: Discontinuation of antipsychotic treatment at early phases increases the risk of poor adherence to maintenance drug therapy. Differences among antipsychotics in terms of effectiveness may determine a good adherence to treatment. OBJECTIVES: The aim of this study is to compare the clinical effectiveness of aripiprazole, ziprasidone and quetiapine in the treatment of first-episode schizophrenia spectrum disorders at 1 year. METHOD: From October 2005 to January 2011 a prospective, randomized, open-label study was undertaken. Two hundred two first-episode drug-naïve patients were randomly assigned to aripiprazole (N = 78), ziprasidone (N = 62), or quetiapine (N = 62) and followed up for 1 year. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted in the analysis for clinical efficacy. RESULTS: The overall dropout rate at 1 year was 13.37 %. The treatment discontinuation rate differed significantly between treatment groups (aripiprazole = 43.6 %, ziprasidone = 66.1 % and quetiapine = 82.3 %) (χ 2 = 22.545; p < 0.001). Insufficient efficacy in the group of quetiapine is the most important reason for differences in discontinuation rates between agents (χ 2 = 19.436; p < 0.001). The mean time to all-cause discontinuation was significantly different between groups (LogRank = 30.732 p < 0.001). The profile of extrapyramidal symptoms varies between treatments. Patients on ziprasidone were more likely to be prescribed antidepressants. CONCLUSIONS: First episode patients treated with quetiapine have a higher risk of treatment discontinuation at midterm due to insufficient efficacy. Establishing differences between SGAs may help clinicians on prescribing decision for treatment of individuals presenting with first-episode non-affective psychosis.
RCT Entities:
RATIONALE: Discontinuation of antipsychotic treatment at early phases increases the risk of poor adherence to maintenance drug therapy. Differences among antipsychotics in terms of effectiveness may determine a good adherence to treatment. OBJECTIVES: The aim of this study is to compare the clinical effectiveness of aripiprazole, ziprasidone and quetiapine in the treatment of first-episode schizophrenia spectrum disorders at 1 year. METHOD: From October 2005 to January 2011 a prospective, randomized, open-label study was undertaken. Two hundred two first-episode drug-naïve patients were randomly assigned to aripiprazole (N = 78), ziprasidone (N = 62), or quetiapine (N = 62) and followed up for 1 year. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted in the analysis for clinical efficacy. RESULTS: The overall dropout rate at 1 year was 13.37 %. The treatment discontinuation rate differed significantly between treatment groups (aripiprazole = 43.6 %, ziprasidone = 66.1 % and quetiapine = 82.3 %) (χ 2 = 22.545; p < 0.001). Insufficient efficacy in the group of quetiapine is the most important reason for differences in discontinuation rates between agents (χ 2 = 19.436; p < 0.001). The mean time to all-cause discontinuation was significantly different between groups (LogRank = 30.732 p < 0.001). The profile of extrapyramidal symptoms varies between treatments. Patients on ziprasidone were more likely to be prescribed antidepressants. CONCLUSIONS: First episode patients treated with quetiapine have a higher risk of treatment discontinuation at midterm due to insufficient efficacy. Establishing differences between SGAs may help clinicians on prescribing decision for treatment of individuals presenting with first-episode non-affective psychosis.
Authors: Rajiv Tandon; R H Belmaker; Wagner F Gattaz; Juan J Lopez-Ibor; Ahmed Okasha; Bruce Singh; Dan J Stein; Jean-Pierre Olie; W Wolfang Fleischhacker; Hans-Juergen Moeller Journal: Schizophr Res Date: 2008-02-19 Impact factor: 4.939
Authors: Benedicto Crespo-Facorro; Rocío Pérez-Iglesias; Ignacio Mata; Victor Ortiz-Garcia de la Foz; Obdulia Martínez-Garcia; Elsa M Valdizan; José L Vazquez-Barquero Journal: J Clin Psychopharmacol Date: 2013-04 Impact factor: 3.153
Authors: Robert Kerwin; Bruno Millet; Erik Herman; Csaba M Banki; Henrik Lublin; Miranda Pans; Linda Hanssens; Gilbert L'Italien; Robert D McQuade; Jean-Noël Beuzen Journal: Eur Psychiatry Date: 2007-06-07 Impact factor: 5.361
Authors: Joseph P McEvoy; Jeffrey A Lieberman; Diana O Perkins; Robert M Hamer; Hongbin Gu; Arthur Lazarus; Dennis Sweitzer; Christina Olexy; Peter Weiden; Stephen D Strakowski Journal: Am J Psychiatry Date: 2007-07 Impact factor: 18.112
Authors: Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; John M Kane; Christoph U Correll Journal: World Psychiatry Date: 2019-06 Impact factor: 49.548
Authors: Marcos Gómez-Revuelta; José María Pelayo-Terán; María Juncal-Ruiz; Víctor Ortiz-García de la Foz; Javier Vázquez-Bourgon; Ana González-Pinto; Benedicto Crespo-Facorro Journal: Int J Neuropsychopharmacol Date: 2018-12-01 Impact factor: 5.176
Authors: Marcos Gómez-Revuelta; José María Pelayo-Terán; María Juncal-Ruiz; Javier Vázquez-Bourgon; Paula Suárez-Pinilla; Rodrigo Romero-Jiménez; Esther Setién Suero; Rosa Ayesa-Arriola; Benedicto Crespo-Facorro Journal: Int J Neuropsychopharmacol Date: 2020-04-23 Impact factor: 5.176